Differential Expression of Matrix Metalloproteinases and Tissue Inhibitors and Extracellular Matrix Remodeling in Aortic Regurgitant Hearts

The Division of Cardiovascular Medicine and The Howard Gilman Institute for Heart Valve Disease, State University of New York Downstate Medical Center, 47 East 88th Street, New York, NY 10128, USA.
Cardiology (Impact Factor: 2.18). 02/2009; 113(3):161-8. DOI: 10.1159/000187723
Source: PubMed


Myocardial fibrosis in experimental aortic regurgitation (AR) features abnormal fibronectin with normal collagen content, but the relevant degradative processes have not been assessed.
To elucidate these degradative processes, mRNA (Northern) and protein levels (Western) of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), as well as MMP activity (zymography), were measured in cardiac fibroblasts (CF) from New Zealand white rabbits with experimental AR paired with normals (NL). Collagen and fibronectin were quantified by immunohistochemical staining.
In AR CF versus NL CF, MMP-2 and -14 mRNA and protein were increased (both p < 0.005), while TIMPs 1-3 were slightly decreased (p < 0.05-0.005; TIMP-4 undetectable). Gelatinase activity in AR CF was 1.7 times that in NL CF (p < 0.005); fibronectinase activity was unaffected. The Jun N-terminal kinase (JNK) inhibitor SP600125 suppressed MMP-2 protein (0.4-fold, p < 0.05) and mRNA (0.7-fold, p < 0.005) in AR CF; MMP-2 levels in NL CF were unaffected. AR MMP-9 mRNA, protein and activity were low and indistinguishable from NL. In left ventricular tissue, fibronectin was increased 1.9-fold (AR vs. NL, p < 0.05). Total AR collagen was indistinguishable from NL, but the collagen III to collagen I isoform ratio decreased (0.4-fold, p < 0.05).
Collagen is relatively deficient in AR fibrosis, due at least in part to upregulated MMPs and downregulated TIMPs; fibronectinase is unaltered. JNK-dependent regulation may stimulate both MMP-2 and fibronectin expression in AR, providing a potential therapeutic target.

7 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Actual interconnected power systems are very large structures which suffer from a large gap between electricity demand and generation and from an inadequate transmission capacity of interconnection lines. In such systems, blackouts have become an all too common an occurrence. This paper proposes a method to reinforce the power systems by insertion of FACTS (flexible alternating current transmission system) devices, which are optimal placed in order to eliminate the dangerous contingencies of the systems and to prevent by this way the apparition of blackout if outages occurs. The FACTS devices are optimal placed in order to maximizing the power system security, the optimization is carried out using three parameters: the location of FACTS devices, their type and their sizes. For this purpose we developed a hybrid software based on GAs (genetic algorithms), which uses Matlabtrade and the EUROSTAGtrade software for load flow calculations. The proposed procedures are successfully tested on an IEEE 14-bus power system
    Future Power Systems, 2005 International Conference on; 12/2005
  • [Show abstract] [Hide abstract]
    ABSTRACT: The mode of action of the somatostatin analog octreotide on neuro-endocrine tumour proliferation is largely unknown. Overexpression of the proto-oncogene Akt/PKB (protein kinase B) has been demonstrated in certain neuro-endocrine tumours: Akt activates downstream proteins including mTOR and p70S6K, which play an important role in cell proliferation. RAD001 (everolimus) is a novel agent that is being trialled in the treatment of neuro-endocrine tumours, and is known to interact with mTOR. We explored the mechanism of action of octreotide, RAD001, and their combination on cell proliferation and kinase activation in a neuro-endocrine tumour cell line (rat insulinoma cell line, INS1). Proliferation assays were used to determine the effects of octreotide, RAD001, and their combination on cell proliferation. Western blotting was used to characterize the expression of phosphorylated Akt, phosphorylated TSC2, phosphorylated mTOR, and phosphorylated 70S6K. Treatment with octreotide and RAD001 inhibited proliferation and attenuated phosphorylation of all downstream targets of Akt: TSC2, mTOR, and p70S6K. In this cell model, octreotide and RAD001 appear to act through a similar pathway and inhibit the Akt-mTOR-p70S6 kinase pathway downstream of Akt. There may be some overlapping effects of the two inhibitors on the mTOR pathway, although it is likely that other additional effects may differentiate the two agents.
    Neuroendocrinology 02/2008; 87(3):168-81. DOI:10.1159/000111501 · 4.37 Impact Factor
  • Source

    JACC. Cardiovascular imaging 02/2009; 2(1):56-7. DOI:10.1016/j.jcmg.2008.11.002 · 7.19 Impact Factor
Show more